Percutaneous coronary intervention in chronic kidney disease patients

Journal of Nephrology

Volumn 17, Issue 3, 2004, Pages 364-368

  Tadros, George M ^a   Herzog, Charles A ^b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c United States Renal Data System   (United States)

Author keywords

Cardiovascular disease; Chronic kidney disease; Coronary artery bypass grafting; End stage renal disease; Percutaneous coronary intervention; Revascularization

Indexed keywords

ABCIXIMAB; ACETYLCYSTEINE; ANTIANGINA PECTORIS AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN;

ANGINA PECTORIS; ANGIOCARDIOGRAPHY; BLEEDING; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS SURGERY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY TRANSPLANTATION; LONG TERM CARE; MORBIDITY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESTENOSIS; RETROSPECTIVE STUDY; REVIEW; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; CORONARY DISEASE; CORONARY RESTENOSIS; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; STENTS; THROMBOLYTIC THERAPY;

EID: 4243107389     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. National Institute of Diabetes and Digestive and Kidney Diseases. Renal Data System. USRDS 2000 Annual Data Report. (NIH publication no.00-3176), 583-689. 2000. Bethesda MD.
2. Luke RG. Chronic renal failure; a vasculopathic state. N Engl J Med 1998; 339: 841-3.
3. Amann K, Ritz E. Cardiac disease in chronic uremia: pathophysiology. Adv Ren Replace Ther 1997; 4: 212-24.
4. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, Berger PB. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39: 1113-9.
5. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patient on long-term dialysis. N Engl J Med 1998; 339: 799-805.
6. Herzog CA, Ma JZ, Collins AJ. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002; 106: 2207-11.
7. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 2002; 144: 226-32.
8. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003; 42: 201-8.
9. Manske CL, Wang Y, Rector TS, Wilson RF, White CW. Coronary revascularization in insulin-dependent diabetic patients with chronic renal failure. Lancet 1992; 340: 998-1002.
10. Szczech LA, Reddan DN, Owen WF, Califf R, Racz M, Jones RH, Hannan EL. Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int 2001; 60: 292-9.
11. Reddan DN, Szczech LA, Tuttle RH, Shaw LK, Jones RH, Schwab SJ, Smith MS, Califf RM, Mark DB, Owen WF Jr. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol 2003; 14: 2373-80.
12. Ivens K, Gradaus F, Heering P, Schoebel FC, Klein M, Schulte HD, Strauer BE, Grabensee B. Myocardial revascularization in patients with end-stage renal disease: comparison of percutaneous transluminal coronary angioplasty and coronary artery bypass grafting. Int Urol Nephrol 2001; 32: 717-23.
13. Rubenstein MH, Harrell LC, Sheynberg BV, Schunkert H, Bazari H, Palacios IF. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation 2000; 102: 2966-72.
14. Keeley EC, Kadakia R, Soman S, Borzak S, McCullough PA. Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes. Am J Cardiol 2003; 92: 509-14.
15. Malanuk RM, Nielsen CD, Theis P, Assey ME, Usher BW, Leman RB. Treatment of coronary artery disease in hemodialysis patients: PTCA vs. stent. Catheter Cardiovasc Interv 2001; 54: 459-63.
16. Gruberg L, Waksman R, Ajani AE. The effect of intracoronary radiation for the treatment of recurrent in-stent restenosis in patients with chronic renal failure. J Am Coll Cardiol 2001; 38: 1049-53.
17. Sagripanti A, Cozza V, Baicchi U, Camici M, Cupisti A, Barsotti G. Increased thrombin generation in patients with chronic renal failure. Int J Clin Lab Res 1997; 27: 72-5.
18. Lovenox (Package Insert). Bridgewater, NJ. Aventis Pharmaceuticals, Inc.; 2003.
19. Collet JP, Montalescot G, Fine E, Golmard JL, Dalby M, Choussat R, Ankri A, Dumaine R, Lesty C, Vignolles N, Thomas D. Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. J Am Coll Cardiol 2003; 41: 8-14.
20. Spirder SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM; ESSENCE and TIMI 11B Investigators. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003; 146: 33-41.
21. Chew DP, Bhatt DL, Kimball W, Henry TD, Berger P, McCullough PA, Feit F, Bittl JA, Lincoff AM. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol 2003; 92: 919-23.
22. Sagripanti A, Barsotti G. Bleeding and thrombosis in chronic uremia. Nephron 1997; 75: 125-39.
23. Gawaz MP, Dobos G, Spath M, Schollmeyer P, Gurland HJ, Mujais SK. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J Am Soc Nephrol 1994; 5: 36-46.
24. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol 2003; 41: 718.
25. Jeremias A, Bhatt DL, Chew DP, Ziada KM, Albirini A, Brener SJ, Lincoff AM, Topol EJ, Ellis SG. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency Am J Cardiol 2002; 89: 1209-11.
26. Best PJ, Lennon R, Gersh BJ, Ting HH, Rihal CS, Bell MR, Herzog CA, Holmes DR Jr, Berger PB. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Am Heart J 2003; 146: 213-14.
27. Januzzi JL Jr, Snapinn SM, DiBattiste PM, Jang IK, Theroux P. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation 2002; 105: 2361-6.
28. Reddan DN, O'Shea JC, Sarembock IJ, Williams KA, Pieper KS, Santoian E, Owen WF, Kitt MM, Tcheng JE. Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). Am J Cardiol 2003; 91: 17-21.
29. Physicians' Desk Reference. 53rd Edition. Montvale, NJ. Medical Economics Co.,1999.
30. Birck R, Krzossok S, Markowetz E, Schnulle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003; 362: 598-603.
31. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 1999; 72: 701-3.
32. Marenzi G, Marana I, Lauri G, Assanelli E, Grazi M, Campodonico J, Trabattoni D, Fabbiocchi F, Montorsi P, Bartorelli AL. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003; 349: 1333-40.
33. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
34. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, Topol EJ; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-20.
35. Kaufman JS, Fiore L, Hasbargen JA, O'Connor TZ, Perdriset G. A pharmacodynamic study of clopidogrel in chronic hemodialysis patients. J Thromb Thrombolysis 2000; 10: 127-31.